KDM4B plays an oncogenic role in breast cancer by upregulating estrogen receptor α (ERα) signaling, whereas KDM4B is transcriptionally targeted by ERα, forming a feed-forward regulatory loop [5–7]. Here, ESR1 is linked to breast carcinoma.